Fewer than one in 10 patients who could benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it releases its initial recommendations on the therapies.
Considering over a billion individuals worldwide now living with obesity, it is calling for increased and just availability to these injectable treatments.
According to forecasts, over two billion will be living with obesity by 2030 without intervention.
"Our new guidelines recognises that obesity is a long-term condition that can be addressed with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to universal availability to the treatments that can assist patients in reducing considerable weight, explains the organization.
Skinny Jab Shortage
Even under the present most favorable case, the production of these medications could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline encourages nations and manufacturers to increase access, by strategies including licensing agreements.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Jabs Function
These medications imitate a natural hormone to delay gastric emptying, reduce hunger and increase satiety so people consume fewer calories.
Patients commonly start to lose weight after several weeks of commencing the weekly injections.
Studies suggests people may put most of the weight back on a year later of discontinuing the treatment, because their usual hunger return.
Being above a healthy weight raises your chance for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns people in countries worldwide and was associated with millions of deaths worldwide in 2024, per the health agency.
